ArticleObesity surgery2026
Triglyceride-to-HDL Cholesterol Ratio is Associated with Hepatic Steatosis but not Fibrosis in Patients with Severe Obesity: A Cross-Sectional Study.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent among individuals with severe obesity. The triglyceride-to-high-density lipoprotein cholesterol ratio (TG/HDL-C) is an accessible surrogate marker of insulin resistance, but its association with hepatic steatosis and fibrosis in candidates for metabolic and bariatric surgery remains incompletely defined.
methodsThis retrospective cross-sectional study included 99 patients undergoing preoperative evaluation for metabolic and bariatric surgery between 2020 and 2024. Hepatic steatosis was assessed by ultrasonography and liver fibrosis by elastography. Associations with TG/HDL-C were examined using categorical analyses and multivariable logistic regression. Because diabetes perfectly predicted hepatic steatosis, Firth penalized logistic regression was used for the primary adjusted analysis.
resultsThe cohort included 61 women (61.6%), with a mean age of 37.0 ± 9.8 years and body mass index of 40.4 ± 4.2 kg/m². Hepatic steatosis was present in 81 of 99 patients (81.8%), whereas fibrosis was identified in 35 of 98 patients with evaluable elastography (35.7%). Higher TG/HDL-C categories were associated with hepatic steatosis (p = 0.0016). After adjustment, each unit increase in TG/HDL-C was associated with higher odds of steatosis (adjusted odds ratio, 2.23; 95% CI, 1.22-4.08; p = 0.0090). TG/HDL-C showed moderate discrimination for steatosis (area under the curve, 0.763; 95% confidence interval, 0.632-0.868), with an exploratory optimal threshold of 2.17 (79.0% sensitivity and 66.7% specificity). In contrast, TG/HDL-C was not associated with fibrosis after adjustment (adjusted odds ratio, 0.84; 95% confidence interval, 0.63-1.10; p = 0.209) and showed no discriminatory ability for fibrosis (area under the curve, 0.494).
conclusionsTG/HDL-C was independently associated with ultrasonographically detected hepatic steatosis and showed moderate discriminatory performance in patients with severe obesity undergoing evaluation for metabolic and bariatric surgery. However, it was not associated with fibrosis assessed by elastography. These findings support TG/HDL-C as a potential low-cost adjunct for identifying steatosis, but not as a substitute for fibrosis-specific assessment.
Indexed as
Identifiers
42616239What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.